Human Cancer Panel Has Six Biomarkers

Each of the biomarkers has been identified in various tumor types including lung, breast, prostate, and colorectal cancer.

The panel demonstrates significance of assessing biomarkers that change from response to the presence of cancer cells, making it valuable for studying the biochemical mechanisms and signals of cancer.

The assays can be used to quantify these biomarkers in serum, plasma, and cell/tissue culture supernatant samples. Each panel includes all components to run the assay, standards, and quality controls for each plex and can be easily adapted for high throughput automation. The panel is highly sensitive, offering excellent intra- (< 11%) and inter-assay (< 10%) precision. Developed by the Millipore Corp. (Billerica, MA, USA; www.millipore.com), the Beadlyte human cancer biomarker panel is suitable for clinical studies and research.

Dr. Gil Mor, from Yale University (New Haven, CT, USA), used the panel in a study to detect all stages of ovarian cancer. The profile of the six biomarkers isolated from serum was used with a unique algorithm developed by Dr. Mor's laboratory to discriminate accurately between ovarian cancer patients and healthy subjects.


Related Links:
Millipore
Yale University